THBS1 + Macrophages Exacerbate Modic Changes via SDC4‐Dependent Activation of NLRP3 Inflammasome
Advanced Science · 2026
DOI: 10.1002/advs.76318 ↗At a glance
Journal article in Advanced Science, 2026. Written by Xiangxi Kong and 16 co-authors. Institution: Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P. R. China. Major MEDLINE topics: Macrophages, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Thrombospondin 1. 54 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China.
Abstract (original language)
Modic changes (MCs) in the lumbar vertebral endplates are a common imaging finding in patients with low back pain. Their pathogenesis and progression are closely linked to the local immune microenvironment, underscoring the need to investigate the immunomodulatory mechanisms involved in MCs. Here, we identified the THBS1 + macrophages displaying a strongly pro‐inflammatory phenotype. The THBS1 + macrophages were enriched at lesion sites in both human lumbar MCs specimens and the C. acnes‐induced mouse model of MC. In vitro, C. acnes and its key metabolites promoted THBS1 expression in macrophages via Toll‐like receptor (TLR) signaling, while TLR inhibition alleviated MCs by suppressing this macrophage subset. Notably, conditional knockout of THBS1 in macrophages effectively attenuated C. acnes‐induced MCs progression. Mechanistically, we identified syndecan‐4 (SDC4) on endplate chondrocytes as a functional receptor for macrophage‐derived THBS1. THBS1–SDC4 engagement activated p38 phosphorylation, leading to transcriptional upregulation of the NLRP3 inflammasome and amplified inflammatory responses in chondrocytes. Conversely, SDC4 silencing mitigated MCs progression. Collectively, this study delineates a mechanism by which THBS1 + macrophages exacerbate lumbar endplate MCs through the SDC4–p38–NLRP3 axis. These findings provide a novel theoretical framework and highlight THBS1 and SDC4 as potential immunotherapeutic targets for modulating disc degeneration.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P. R. China.
- Key Laboratory of Musculoskeletal System Degeneration and Regeneration Translational Research of Zhejiang Province, Hangzhou, P. R. China.
- Department of Wound Healing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, P. R. China.
- Department of Orthopaedic Surgery, The Affiliated LiHuiLi Hospital of Ningbo University, Ningbo, P. R. China.
- School of Medicine, Hangzhou City University, Hangzhou, P. R. China.
- Department of Orthopedics Surgery, Ningbo No.2 Hospital, Ningbo, Zhejiang, P. R. China.
ORCID profiles: Junhui Liu, Jian Chen, Zhi Shan
Funding
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation of China
Cite
APA
Kong, X., Xue, Q., Wei, X., Li, J., Huang, B., Chen, W., Cai, Z., Yang, T., Yao, C., Jin, J., Cai, B., Zhang, X., Liu, J., Wu, H., Chen, J., Shan, Z., & Zhao, F. (2026). THBS1 + Macrophages Exacerbate Modic Changes via SDC4‐Dependent Activation of NLRP3 Inflammasome. Advanced Science. https://doi.org/10.1002/advs.76318
Vancouver
Kong X, Xue Q, Wei X, Li J, Huang B, Chen W, et al. THBS1 + Macrophages Exacerbate Modic Changes via SDC4‐Dependent Activation of NLRP3 Inflammasome. Advanced Science. 2026. doi:10.1002/advs.76318
BibTeX
@article{Kong2026,
author = {Kong, Xiangxi and Xue, Qize and Wei, Xiaoan and Li, Jie and Huang, Bao and Chen, Weishao and Cai, Zimin and Yang, Tao and Yao, Chengjun and Jin, Jiayan and Cai, Bohan and Zhang, Xuyang and Liu, Junhui and Wu, Haihao and Chen, Jian and Shan, Zhi and Zhao, Fengdong},
title = {THBS1 + Macrophages Exacerbate Modic Changes via SDC4‐Dependent Activation of NLRP3 Inflammasome},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76318}
}
EUVIMED